JP2025518493A5 - - Google Patents
Info
- Publication number
- JP2025518493A5 JP2025518493A5 JP2024566539A JP2024566539A JP2025518493A5 JP 2025518493 A5 JP2025518493 A5 JP 2025518493A5 JP 2024566539 A JP2024566539 A JP 2024566539A JP 2024566539 A JP2024566539 A JP 2024566539A JP 2025518493 A5 JP2025518493 A5 JP 2025518493A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- cdr1
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263341944P | 2022-05-13 | 2022-05-13 | |
| US63/341,944 | 2022-05-13 | ||
| PCT/US2023/066819 WO2023220626A2 (en) | 2022-05-13 | 2023-05-10 | 5t4 binding agents and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025518493A JP2025518493A (ja) | 2025-06-17 |
| JP2025518493A5 true JP2025518493A5 (cg-RX-API-DMAC7.html) | 2026-05-14 |
Family
ID=88731098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024566539A Pending JP2025518493A (ja) | 2022-05-13 | 2023-05-10 | 5t4結合剤及びその使用 |
Country Status (16)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025180472A1 (zh) * | 2024-02-28 | 2025-09-04 | 惠和生物技术(上海)有限公司 | 单克隆抗体分子及其用途 |
| WO2026010986A1 (en) * | 2024-07-05 | 2026-01-08 | Solve Therapeutics, Inc. | 5t4-binding proteins |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG170091A1 (en) * | 2006-03-10 | 2011-04-29 | Wyeth Corp | Anti-5t4 antibodies and uses thereof |
| WO2016034666A1 (en) * | 2014-09-04 | 2016-03-10 | Cellectis | Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy |
| KR20220030934A (ko) * | 2019-05-31 | 2022-03-11 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 항-gal9 면역-억제 결합 분자 |
-
2023
- 2023-05-10 TW TW112117412A patent/TW202400639A/zh unknown
- 2023-05-10 WO PCT/US2023/066819 patent/WO2023220626A2/en not_active Ceased
- 2023-05-10 IL IL316788A patent/IL316788A/en unknown
- 2023-05-10 CN CN202380053588.4A patent/CN119546643A/zh active Pending
- 2023-05-10 AU AU2023267764A patent/AU2023267764A1/en active Pending
- 2023-05-10 KR KR1020247040741A patent/KR20250024530A/ko active Pending
- 2023-05-10 PE PE2024002518A patent/PE20251275A1/es unknown
- 2023-05-10 CN CN202510753500.0A patent/CN120607619A/zh active Pending
- 2023-05-10 JP JP2024566539A patent/JP2025518493A/ja active Pending
- 2023-05-10 CA CA3252305A patent/CA3252305A1/en active Pending
- 2023-05-10 CR CR20240489A patent/CR20240489A/es unknown
- 2023-05-10 US US18/863,565 patent/US20250326858A1/en active Pending
- 2023-05-10 EP EP23804474.7A patent/EP4522660A4/en active Pending
-
2024
- 2024-11-08 MX MX2024013871A patent/MX2024013871A/es unknown
- 2024-11-11 DO DO2024000234A patent/DOP2024000234A/es unknown
- 2024-11-11 CL CL2024003442A patent/CL2024003442A1/es unknown
- 2024-11-12 CO CONC2024/0015383A patent/CO2024015383A2/es unknown
-
2025
- 2025-08-26 CL CL2025002572A patent/CL2025002572A1/es unknown